PCSK9 and atherosclerosis: Moreover, a meta-analysis of five randomized trials emphasized non-statin lipid-lowering therapy with a small-interfering RNA, inclisiran, that reduces LDL-C, PCSK9, and total cholesterol levels in individuals with ASCVD [80].